anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Questions remain concerning the optimal duration of simulator training for flexible optical bronchoscopic (FOB) intubation. The investigators' previous study demonstrated that an exponential curve could fit the learning curve of FOB intubation training on a high-fidelity simulator after logarithmical transformation of the procedure time. In brief, trainees could achieve a plateau of the learning curve after several procedures, i.e., further training might provide only negligible progress. According to the investigators' preliminary study, the training time for the majority might be less than one hour which is the dominant duration of simulator training in previous studies. By generating a learning curve from the initial several procedures on a simulator, it is possible to predict when a trainee could grow saturated individually. It is hypothesized that this new learning-curve-based training modality could contribute to non-inferior FOB intubation time in patients compared with the reference fixed-training-time (1 hour) training modality, albeit with less training time. The noninferiority margin is defined according to the reported FOB intubation time and the training effect in previous studies. Moreover, it is plausible that this new training modality might even present a higher success rate and better performance of FOB intubation, considering each trainee following the new training has to achieve the individual goal that precludes an outlier from failing to have enough training that might occur in reference fixed-training-time training.
PURPOSE: To obtain a hair tonic having excellent preventing effect on falling off of hair and promoting effect on hair production, comprising an extract of a plant for a crude medicine from Indonesia as an active ingredient. CONSTITUTION: This hair tonic contains 0.005-20wt.% of one or more selected from Orange aring derived from Eclipta alba L. of the family Asteraceae, Srigading derived from Nyctanthes arbor-tristis L. of the family Oleaceae, Jangkang derived from Sterculia foetida L of the family Sterculiaceae, Lempyang derived from Zingiber aromaticum Mal. of the family Zingiberaceae, Meniran derived from Phyllanthuss niruri L. of the family Euphorbiaceae, Mrico bolong derived from Melaleuca Leucadindra of the family Myrtaceae and Temu kunei derived from Boesenbergia pandurata of the family Zingiberaceae as an active ingredient. The plant is extracted with a solvent (e.g. methanol). The hair tonic is percutaneously administered by direct application or spraying to skin. Adose is 0.01-100mg/kg/day.
Because almost all drug trials for Alzheimer's disease (AD) have failed, developing non-pharmacological interventions with strong potential to prevent or delay the onset of AD in high-risk populations (e.g., those with mild cognitive impairment \[MCI\]) is critically important. Aerobic exercise and cognitive training are 2 promising interventions for preventing AD. Aerobic exercise increases aerobic fitness, which in turn improves brain structure and function, while cognitive training improves selective neural function intensively. Hence, combined Aerobic exercise and Cognitive Training (ACT) may very well have an additive or synergistic effect on cognition by complementary strengthening of different neural functions. Few studies have tested ACT's effects, and those studies have reported discrepant findings, largely due to varying ACT programs. The purpose of this single-blinded, 2×2 factorial Phase II randomized controlled trial (RCT) is to test the efficacy and additive/synergistic effects of a 6-month combined cycling and speed of processing (SOP) training intervention on cognition and relevant mechanisms (aerobic fitness, AD signature cortical thickness, and functional connectivity in the default mode network \[DMN\]) in older adults with amnestic MCI (aMCI).
Levothyroxine (LT4) and placebo (a look-alike inactive substance, a "sugar pill") Patients in the LT4 group will be started at a dose of 1.6 mcg/Kg (52 The VCU Investigational Pharmacy will over-encapsulate LT4 plus placebo, in "AM" and "PM" color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation.
An anti-microbial composition for providing a therapeutic application onto a living being. The composition includes from about 0.001 wt. % to about 0.20 wt. % chlorite compound and from about 0.001 wt. % to about 0.05 wt. % peroxy compound. The anti-microbial composition of the present invention is composed to remain intact without being degraded to generate chlorine dioxide during storage at about a room temperature. The anti-microbial composition of the present invention is at a pH range between about 6.0 and about 8.8.
The Undersea Medicine Program at the Office of Naval Research has invited Indiana University, Rutgers and Colorado State University, to explore the potential of the medication, Mirabegron, to improve the cold tolerance of Navy personnel. Indiana University will submit the formal application for research funding. Research activities at Colorado State University will be supported by a sub-contact from Indiana University.

The project will address four hypotheses. One of these hypotheses will be investigated exclusively at Colorado State University during the second year of the project. The proposed activities at Colorado State University will be unique; the link to activities performed by Indiana University and Rutgers is thematic only.

Specialized Navy personnel are required to undertake duties while immersed in cold water for prolonged periods. These dives regularly require the use of external thermal protection (i.e., wet suits and dry suits). However, external thermal protection during prolonged cold-water diving is often times insufficient to maintain body temperature and thermal comfort, thereby potentially negatively impacting the safety and success of diving missions. Accordingly, developing an alternative strategy that can improve tolerance to cold-water immersion is of important interest to Navy divers and special forces. In this regard, the pharmaceutical, mirabegron, may hold considerable promise to mitigate the negative effects of cold-water immersion on cold-water tolerance by increasing thermogenesis (the generation of heat). Mirabegron (Myrbetriq®, extended-release tablet, Astellas Pharma), is a medication approved by the Food and Drug Administration for the treatment of overactive bladder. In 2020, it was the 160th most commonly prescribed medication in the United States, with more than three million prescriptions. The mechanism of action is stimulation of beta-3-adrenergic receptors (receptors that are usually stimulated by the sympathetic nervous system). Mirabegron is also known to stimulate brown fat, a metabolically active, heat-generating tissue. The overall goals of the project are to determine the efficacy of acute mirabegron administration to improve cold tolerance and determine if mirabegron can accentuate thermogenesis during sympathetic activation.
All participants will be advised to lead healthy lifestyle habits according to the recommendations of the "Plan for the Promotion of Physical Activity and Balanced Eating of the Junta de Andalucía" http://www.juntadeandalucia.es/educacion/webporta/ishareservlet/content/86cf9950-abaa-403b-9fc3 9bc5ecae4614. A submaximal stress test will be performed at the beginning and end of the intervention. Before the test, the participants will become familiar with the measuring instrument with a warm-up that allowed them a gain in understanding the gear system. The test will start with a pedaling cadence of 50 revolutions, with an output power of 0 W, increasing by 25 W every 2 minute period. During the test there will be a continuous recording of blood pressure, heart rate and maximum oxygen consumption (VO2max). With this stress test, the aerobic and anaerobic threshold of each participant will be determined to mark the intensity of work at which each subject must perform physical activity in the intervention period.

The interventions of the 2 experimental groups are carried out with a frequency of 3 weekly trainings, for a total period of 16 weeks. The intensity of the training will be assigned to each subject individually based on the stress test performed in the previous phase. Experimental group 1 (HIIT): The HIIT protocol will be carried out after a 10-minute warm-up period with joint mobility exercises and dynamic stretching. The intervention will consist of training in which intense work intervals and active rest periods are combined using a cycle ergometer. The session will be divided into 4 intervals of 4 minutes duration at an intensity of 85-95% of the maximum heart rate \[HRM\], individually controlled during all sessions (Polar Team pro®), followed by active rest intervals 3 minute duration at 50-70% FCM. After the training, there will be a 10-minute cool down of gentle pedaling and joint range exercises. Experimental group 2 (MICT): Heating phase identical to the previous one. Subsequently, the participants will perform a training on the cycle ergometer with an intensity close to 70% FCM maintained for 40 minutes and will be controlled individually (Polar Team pro®). The session will conclude with a cool down phase identical to the previous one. Control group (CTRL): The participants will receive general advice on the positive effects of the regular practice of physical activity, and they will be given the guide of recommendations for the promotion of physical activity published by the Junta de Andalucía: http: // www.juntadeandalucia.es/salud/servicios/contenidos/andaluciaessalud/docs/130/Guia_Recomendaciones_AF.pdf
The patients of experimental arm take study drug Efesovir twice a day as an antiviral therapy in dose 0.125 ml / kg. Daily dose of Efesovir: 0.250 ml / kg. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
ABSTRACT OF THE DISCLOSURE            A biologically active substance with standardized effect is proposed, containing in a physiological medium at least one histone, particularly an H2 histone or an active region of this histone.  The use of histones and/or histone segments for producing such a preparation is also proposed.  The histones can be obtained from a biological source material, e.g. calf thymus.  Since H2a and H2b histones from cows and humans are identical, histones obtained for the preparation according to the invention can also be used in human medicine applications. Preparations according to the invention may contain only one evolutionally variable segment of at least one histone, in particular an H2a or H2b histone.  Such segments can be pro-duced relatively easily by synthetic and/or genetic engineering methods.  The invention is based substantially on the finding that the active area of an immune stimulating or endocrino-logically active histone lies within the evolutionally variable histone segment.  The preparation according to the invention can also be used in immune therapy.  One of its properties is that it can be used as a corticotropine (ACTH), thyroid gland and gonad antagonist and a growth hormone (GH) synergist.  It is also applicable in immunological weaknesses (e.g. in malnutrition) and in the immune deficiencies following thymec-tomy or massive radiation of the thymus for the prevention of radiation-induced leukemia and in cancer treatment and is suitable for diagnostic procedures.
PURPOSE: To impart curls with continuity and soft and smooth cosmetic characteristics to a person's hair treated with a polysaccharide or a polysaccharide derivative by using steam under a specific condition. CONSTITUTION: First, a composition made of a polysaccharide and/or a polysaccharide derivative is applied to a person's hair. This treatment using the polysaccharide can be given before, during, or after stretching a bundle of hairs to make a finally requested hair style. Next, the bundle of hairs soaked with the polysaccharide is kept in contact with gas including steam of at least 75 deg.C for a period not exceeding 2 minutes, and next, air is made to flow all through the bundles of hair speedily at the room temperature, and/or the curled hair is sucked and cooled by air flow. Finally, a mechanical means, which keeps stretching of the bundles of hairs totally treated and set as a requested style, is removed from the hair. In this way, attractive and soft curls can be obtained.
Retinal astrocytic hamartomas (RAH) are benign tumors of glial cells arising from astrocytes in the nerve-fiber layer of the retina. They are often associated with tuberous sclerosis complex (TSC) and, more rarely, neurofibromatosis type 1 (NF1). RAH may be caused by dysregulated tumor suppressors genes TSC1 or TSC2, which play a role in cell cycle regulation in retinal astrocytes via the PDGF-signalling pathway. Downregulation of TSC1 or TSC2 can result in hyperactivation of mTOR. Sirolimus is an inhibitor of mTOR, therefore inhibiting cell growth and proliferation of astrocytes. Systemic mTOR inhibitors (sirolimus and everolimus) have shown impressive reduction in the size of RAH in animal models and many human case series.

This single patient study is investigating the use of concurrent oral and intravitreal Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes to improve intraocular response and reduce duration of treatment. The patient has no other clinical features suggestive of neurofibromatosis and a presumed diagnosis of tuberous sclerosis is being considered, with only two hypopigmented skin lesions noted.
Enhanced liver fibrosis (ELF) score is a noninvasive assessment for liver fibrosis. We aimed to evaluate the performance of changes in ELF score 3 years apart in combination with liver stiffness measurement (LSM)-hepatocellular carcinoma (HCC) score to predict HCC in chronic hepatitis B (CHB) patients. This is a prospective cohort study. Patients who underwent transient elastography (TE) examinations and at intermediate or high risk of HCC defined by LSM-HCC score were invited to repeat the examination about 3 years later. Their serum samples at these two time points were retrieved to assess the ELF score changes. The primary endpoint was HCC. There were 445 CHB patients (males: 73.9%; mean age: 51.6 ± 10.3 years) who received two TE examinations and ELF scores. Among them, 252 (56.6%) and 193 (43.4%) patients were at intermediate and high HCC risk at first assessment defined by LSM-HCC score, respectively. Kaplan-Meier analysis showed that the changes in ELF score could stratify the HCC risk in both intermediate- and high-risk patients defined by LSM-HCC score (p < 0.001 for intermediate-risk group; p = 0.011 for high-risk group). Patients remained having mild or moderate fibrosis at both assessments had the lowest risk of HCC (4.0%), followed by patients with fibrosis regressed (11.3%; p = 0.014) during a mean follow-up of 163 months. Patients remained having or progressed to severe fibrosis were at highest risk of HCC (> 20%). Consistent findings were demonstrated in patients at both intermediate and high risk of HCC defined by LSM-HCC score. Dynamic changes in ELF score provided additional value to LSM-HCC score for stratifying HCC risk in CHB patients.
The EMT-transcription factor ZEB1 is heterogeneously expressed in tumor cells and in cancer-associated fibroblasts (CAFs) in colorectal cancer (CRC). While ZEB1 in tumor cells regulates metastasis and therapy resistance, its role in CAFs is largely unknown. Combining fibroblast-specific Zeb1 deletion with immunocompetent mouse models of CRC, we observe that inflammation-driven tumorigenesis is accelerated, whereas invasion and metastasis in sporadic cancers are reduced. Single-cell transcriptomics, histological characterization, and in vitro modeling reveal a crucial role of ZEB1 in CAF polarization, promoting myofibroblastic features by restricting inflammatory activation. Zeb1 deficiency impairs collagen deposition and CAF barrier function but increases NFκB-mediated cytokine production, jointly promoting lymphocyte recruitment and immune checkpoint activation. Strikingly, the Zeb1-deficient CAF repertoire sensitizes to immune checkpoint inhibition, offering a therapeutic opportunity of targeting ZEB1 in CAFs and its usage as a prognostic biomarker. Collectively, we demonstrate that ZEB1-dependent plasticity of CAFs suppresses anti-tumor immunity and promotes metastasis.
Patients were evaluated four times. In the first consultation, without taking cholinesterase inhibitors (ChEI), after three, six and 12 months taking ChEI.
A system and method are provided for identifying exposure concentrations. The process of determining exposure concentrations may include organizing exposure data, defining parameters, determining elevated exposure concentrations, and providing output results. The exposure data may relate to at least geographical locations, policies, accounts, portfolios, treaties, and other exposure data. The parameters may be defined to include at least an area of analysis, a region of interest, a threshold amount, results parameters, and other parameters. The exposure concentration may include at least defining and locating exposure locations using various techniques. The results may be presented using textual, graphical, or other display schemes. The output may be configured to convey information such as positional accuracy of an identified area, exposure accumulation in a defined area, and other information.
The present invention relates to a nano-conjugate for photodynamic therapy using a polyethylene glycol forest, and a method for preparing the same. More particularly, the present invention provides a polymer nano-conjugate comprising a polyethylene glycol forest surrounding a photosensitizing agent. In the structure of the polymer nano-conjugate, a hydrophilic polyethylene glycol forest surrounds hydrophobic photosensitizing agent molecules individually. Thus, it is possible to reduce an auto-quenching effect of the photosensitizing agent and to induce generation of a high content of singlet oxygen. It is also possible to provide a significantly improved photodynamic effect of killing tumor cells and to avoid side effects substantially. Therefore, the nano-conjugate is useful for photodynamic anti-cancer therapy.
A thiolated gelatine containing carbon is used as an ink.  When dry, the paper is dipped into dimethylsulphoxide to cross-link the gelatine and render the writing waterproof.ALSO:A thiolated polymer such as a thiolated protein or a polysulphide thiol polymer is crosslinked by reaction with dimethyl sulphoxide. Thiolated gelatine hardened and rendered insoluble in this way may be employed in making capsules, medicated films or antiseptic dressings, for coating drugs, for photographic purposes in hot and/or humid climates, or for coating the hands so as to form gloves in situ thereon.  A low molecular weight polysulphide polymer may be contacted with a dimethyl sulphoxide-toluene solution containing thiuram disulphide to produce a high molecular weight elastomer.ALSO:Vitamin A is encased in a gelatin layer by pan coating or by spraying a solution of thiolated gelatin in dimethyl sulphoxide thereon, followed by drying.ALSO:Thiolated gelatin cross-linked with dimethyl sulphoxide is used to coat drugs (e.g. Vitamin A), to make capsules and buccal lozenges to produce medicated films and wound dressings, to make prosthetic implants such as artificial arteries (by coating a fabric tube).  Solutions of the gelatin may be applied to the skin to form gloves (e.g. for surgeons) or depilatory masks.
The study will prospectively include adult patients (\>18 years) with suspected sepsis admitted to Oslo University Hospital, Ullevål (OUH-Ullevål). Patients admitted to the emergency department and managed by the medical rapid response team or the sepsis rapid response team are considered eligible for inclusion. Informed consent will be collected at the emergency department if possible, or within few days, by a clinical investigator or a study nurse. The investigators aim to include 1500 patients treated by the Sepsis Rapid Response Team or Medical Emergency team for possible sepsis. Patients classified to have had other conditions than sepsis in the post hoc assessment will be used as controls. The inclusion period will be 3 years.
The present invention relates to the technical field of polysaccharides. Disclosed are an auricularia auricula polysaccharide, use thereof, and a preparation method therefor. Auricularia auricula, after de-fatting, undergoes initial enzymatic hydrolysis under the action of snailase. Further degradation and extraction are performed by means of H2O2 synergistic ultrasound. Then, under the action of a complex enzyme, deep enzymatic hydrolysis is performed, followed by mixed fermentation of Lactobacillus bulgaricus, Streptococcus thermophilus, and Bifidobacterium longum. The resulting fermented Auricularia auricula polysaccharides undergo a phosphorylation reaction under the action of a phosphorylation reagent and are then subjected to deproteinization, decolorization, and chelation with a zinc salt, such that a polysaccharide-zinc complex is obtained, hence obtaining Auricularia auricula polysaccharides. The preparation method is simple, has high extraction efficiency, and yields Auricularia auricula polysaccharides with high purity, good solubility, and enhanced absorbability. These polysaccharides exhibit great physiological activity, including good anti-inflammatory, anti-aging, and blood sugar-lowering effects. The polysaccharides also possess the effects of enhancing immunity, promoting intellectual development, lowering blood lipids, regulating total cholesterol, and effectively increasing beneficial cholesterol, and have wide application prospects.
BACKGROUND The modified shock index (MSI) is calculated as the ratio of heart rate (HR) to mean arterial pressure (MAP) and has been used to predict the need for massive transfusion (MT) in trauma patients. This retrospective study from a single center aimed to compare the MSI with the traditional shock index (SI) to predict the need for MT in 612 women diagnosed with primary postpartum hemorrhage (PPH) at the Emergency Department (ED) between January 2004 and August 2023. MATERIAL AND METHODS The patients were divided into the MT group and the non-MT group. The predictive power of MSI and SI was compared using the areas under the receiver operating characteristic curve (AUC). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value were calculated. RESULTS Out of 612 patients, 105 (17.2%) required MT. The MT group had higher median values than the non-MT group for MSI (1.58 vs 1.07, P<0.001) and SI (1.22 vs 0.80, P<0.001). The AUC for MSI, with a value of 0.811 (95% confidence interval [CI], 0.778-0.841), did not demonstrate a significant difference compared to the AUC for SI, which was 0.829 (95% CI, 0.797-0.858) (P=0.066). The optimal cutoff values for MSI and SI were 1.34 and 1.07, respectively. The specificity and PPV for MT were 77.1% and 40.2% for MSI, and 83.2% and 45.9% for SI. CONCLUSIONS Both MSI and SI were effective in predicting MT in patients with primary PPH. However, MSI did not demonstrate superior performance to SI.